Search - tctmd.com

Displaying 801 - 820 of 1134

Sort: Relevancy | Date

Presentation TCT 2016

Featured Lecture: The Rationale and Impact of New European Device Regulations

Presenter: Michael J. Mack, Aaron V. Kaplan, Alan G. Fraser

October 31, 2016

News Industry News

Study Indicates That Open Heart Surgery May Be Superior To PCI For Treatment Of Left Main Coronary Artery Disease

October 31, 2016

News Industry News

Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease

October 31, 2016

Presentation TCT 2016

NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Evald H. Christiansen

October 31, 2016

Presentation TCT 2016

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

Presenter: Martin B. Leon, Keith G. Oldroyd, Gregg W. Stone

October 31, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

Presentation TCT 2016

LEADERS FREE: Two-Year Clinical and Subgroup Outcomes From a Prospective, Randomized Trial of a Polymer-Free Drug-Coated Stent and a Bare Metal Stent in Patients With Coronary Artery Disease at High Bleeding Risk

Presenter: David W.M. Muller, Jonathan M. Hill, Philip M. Urban

October 30, 2016

Presentation TCT 2016

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Presenter: David W.M. Muller, Jonathan M. Hill, Runlin Gao

October 30, 2016

Presentation TCT 2016

Featured Lecture: The Digital Health Revolution Will Transform Cardiovascular Disease Management in the Future

Presenter: Juan F. Granada, Louis A. Cannon, Peter J. Fitzgerald

October 30, 2016

Presentation TCT 2016

Featured Lecture: Interventional Innovation is Alive and Well Reflections and Predictions

Presenter: Juan F. Granada, Louis A. Cannon, Elazer R. Edelman

October 30, 2016

News Industry News

Study Confirms Polymer-Free Drug-Coated Stents Safer And More Effective Than Bare-Metal Stents In Patients At Risk For Bleeding Treated With One Month Of DAPT

October 30, 2016

News Industry News

Very Thin-Strut Biodegradable Polymer Everolimus-Eluting And Sirolimus-Eluting Stents Shown To Be Non-Inferior To Durable Polymer Zotarolimus-Eluting Stents In All-Comers With Coronary Artery Disease

October 30, 2016

News Industry News

Study Examines Use of Optical Coherence Tomography Compared to Intravascular Ultrasound and Angiography to Guide Coronary Stent Implantation

October 30, 2016

News Industry News

Study Finds Ridaforolimus-Eluting Stent is Non-Inferior to Zotarolimus-Eluting Stent Based On One-Year Clinical Outcomes

October 30, 2016

Presentation TCT 2016

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, David E. Kandzari

October 30, 2016

Presentation TCT 2016

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Clemens von Birgelen

October 30, 2016

Presentation TCT 2016

ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs IVUS-Guided vs Angio-Guided Stent Implantation in Patients With Coronary Artery Disease

Presenter: Gregg W. Stone, Wayne B. Batchelor, Ziad A. Ali

October 30, 2016

News Opinion Editor's Corner TCT 2016

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Shelley Wood

October 24, 2016

News Features

Grumbling Over Bundling: Cardiologists React Warily to Plans for Lump-Sum Payments for Cardiac Care

Caitlin E. Cox

September 23, 2016

Advertisement

Featured Lecture: The Rationale and Impact of New European Device Regulations

Study Indicates That Open Heart Surgery May Be Superior To PCI For Treatment Of Left Main Coronary Artery Disease

Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease

NOBLE: A Prospective, Randomized Trial Comparing Biolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

EXCEL: A Prospective, Randomized Trial Comparing Everolimus-Eluting Stents and Bypass Graft Surgery in Selected Patients With Left Main Coronary Artery Disease

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

LEADERS FREE: Two-Year Clinical and Subgroup Outcomes From a Prospective, Randomized Trial of a Polymer-Free Drug-Coated Stent and a Bare Metal Stent in Patients With Coronary Artery Disease at High Bleeding Risk

ABSORB II: Three-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

ABSORB China: Two-Year Clinical Outcomes From a Prospective, Randomized Trial of an Everolimus-Eluting Bioresorbable Vascular Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease

Featured Lecture: The Digital Health Revolution Will Transform Cardiovascular Disease Management in the Future

Featured Lecture: Interventional Innovation is Alive and Well Reflections and Predictions

Study Confirms Polymer-Free Drug-Coated Stents Safer And More Effective Than Bare-Metal Stents In Patients At Risk For Bleeding Treated With One Month Of DAPT

Very Thin-Strut Biodegradable Polymer Everolimus-Eluting And Sirolimus-Eluting Stents Shown To Be Non-Inferior To Durable Polymer Zotarolimus-Eluting Stents In All-Comers With Coronary Artery Disease

Study Examines Use of Optical Coherence Tomography Compared to Intravascular Ultrasound and Angiography to Guide Coronary Stent Implantation

Study Finds Ridaforolimus-Eluting Stent is Non-Inferior to Zotarolimus-Eluting Stent Based On One-Year Clinical Outcomes

BIONICS: A Prospective, Randomized Trial of a Ridaforolimus-Eluting Coronary Stent vs a Zotarolimus-Eluting Stent in a More-Comers Population of Patients With Coronary Artery Disease

BIO-RESORT (TWENTE III): A Prospective, Randomized Three-Arm Trial Comparing Two Different Biodegradable Polymer-Based Drug-Eluting Stents and a Durable Polymer-Based Drug-Eluting Stent in an All-Comers Population of Patients With Coronary Artery Disease

ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs IVUS-Guided vs Angio-Guided Stent Implantation in Patients With Coronary Artery Disease

TCT 2016: Inspiration and Perspiration Greet Left Main Stenting, Hoop Dreams, Valve Innovation, and Election Fever

Grumbling Over Bundling: Cardiologists React Warily to Plans for Lump-Sum Payments for Cardiac Care

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content